Evaluation of Clarity Ultrasound Guidance for Prostate Therapy

Prostate Cancer Clinical Trial

— Clarity-Pro  

Official title:

Evaluation of Clarity Ultrasound Guidance for Prostate Therapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02388308
• Other study ID #: 4267
• Status: Completed
• Start date: May 15, 2015
• Est. completion date: June 18, 2018

Study information

• Verified date: June 2018
• Source: Institute of Cancer Research, United Kingdom
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Radiotherapy (RT) is an important treatment for prostate cancer with over 10,000 men receiving RT per year in the UK. Prostate RT aims to deliver radiation dose to the prostate to kill cancer cells whilst minimizing the dose given to surrounding normal tissues, such as the bladder or the rectum. Radiation is delivered in a number of daily treatments which are called 'fractions'. The position of the prostate varies each day and during the radiation delivery. To accurately aim the radiation the prostate needs to be located before daily treatment. Clarity is an ultrasound image guidance system that locates the prostate and monitors its position during treatment. Ultrasound does not give a radiation dose, is non-invasive, provides fast imaging and can easily visualise soft tissues. Before Clarity is implemented the investigators wish to ensure that it can accurately locate and monitor the prostate by comparing Clarity with marker-based techniques in 24 patients. Patients receive markers as part of other trials which are currently recruiting at The Royal Marsden (for example, patients in the DELINEATE trial and the PACE trials receive implanted gold markers and patients in the PROSPARE trial have received electromagnetic markers). Patients who have received or will be receiving markers as part of other studies will be asked to also to take part in this study. This means that there will be no additional intervention for patients as a result of this study. Clarity will be considered a safe and effective imaging system if the mean and standard deviation of the differences between Clarity measurements and marker measurements, of prostate position, are less than 1mm. It is possible that markers will influence the Clarity measurements. To find out if this happens, the mean and standard deviation of Clarity measurements in a group of 24 patients without markers to the group with markers will be compared.

Primary Aim: To evaluate the accuracy of Clarity ultrasound image guidance system for prostate motion estimation during treatment (intra-fraction), by comparison with implanted marker-based image guidance techniques.

Primary Hypothesis: Clarity can be safely used to deliver radiotherapy using similar (within 1mm) treatment margins to those that would be employed if fiducial markers based image guidance techniques were used.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 61
• Est. completion date: June 18, 2018
• Est. primary completion date: June 18, 2018
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Two patient groups and two patient volunteer groups will be recruited:

Groups 1: Patient volunteers who have received radiotherapy for prostate cancer which included a planning CT scan, or who are currently receiving radiotherapy.

Groups 2 and 3:

• Patients receiving radiotherapy for prostate cancer as part of a clinical trial or standard care which includes gold FM or EM insertion

• Patients who have previously received RT for prostate cancer which included EM insertion.

Group 4: Patients who are receiving radiotherapy for prostate cancer and who are not receiving FMs. Attempts will be made to match Group 4 patients BMI and time receiving hormone therapy to patients in group 2 and 3 (see below, section 6.1 recruitment.

Exclusion Criteria:

Groups 1 to 4: Patients who have received prostatectomy.

Groups 2 and 4: Patients receiving less than 6 RT fractions.

Group 4 only: Patients who have received FMs or EMs.

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Device:
• Clarity ultrasound
Ultrasound imaging data will be recorded only. Treatment will not be altered as a result of this study.

Locations

Country	Name	City	State
United Kingdom	The Royal Marsden	Sutton

Sponsors (2)

Lead Sponsor	Collaborator
Institute of Cancer Research, United Kingdom	Royal Marsden NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prostate position (measured in millimeters) measured using Clarity ultrasound and implanted fiducial markers	Mean (and standard deviation) of the differences in prostate position determined using Clarity and that determined using fiducial marker based image guidance during radiotherapy delivery.	Outcome measures will be assessed for each patient during radiotherapy, an average of five weeks.